Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Archives of Dermatological Research · 23.07.2024 · 316 (7)
DOI: 10.1007/s00403-024-03225-4 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Archives of Dermatological Research, online erschienen am 23.07.2024. Verfasst von Eden David und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 1…. Hauptthemen laut MEDLINE: Alopecia Areata, Antibodies, Monoclonal, Humanized, Hair. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alopecia areata (AA) is nonscarring hair loss characterized by Th1 and concomitant Th2 skewing, particularly in atopic patients. Despite novel developments for adult AA, safe and effective treatments for pediatric patients remain limited. Dupilumab, with a well-studied safety profile, may have therapeutic potential for atopic pediatric AA. To evaluate the ability of dupilumab to regrow hair in pediatric AA patients. We conducted a single-center, retrospective, observational study to evaluate hair regrowth [using Severity of Alopecia Tool (SALT)] with dupilumab in 20 children with both AD and AA (age range 5–16 years, mean 10.8 years; baseline SALT range 3–100, mean 54.4). Patient demographics, atopic history, IgE and SALT scores were collected at 12wk follow-up visits, up to > 72wks, to evaluate hair regrowth. Spearman correlations with clinical data were performed. Patients showed clinical improvement over the follow-up period (range 24 to > 72wks, mean 67.6wks) with significant mean(± SD) reduction in SALT at 48wks versus baseline [20.4(± 35.1) vs 54.4(± 37.6), respectively; p < 0.01] and continued improvement up to > 72wks [2.2(± 4.9), p < 0.01]. Baseline SALT positively correlated with disease duration (r = 0.54, p < 0.01), and negatively correlated with improvement in SALT at weeks 24, 36, and 48 (|r|≥ 0.65, p < 0.01 for all comparisons). Baseline IgE positively correlated with improvement in SALT at week 36 (r > 0.60, p < 0.05). Dupilumab was well-tolerated, with no new safety concerns. These real-world data support the utility of dupilumab to safely treat pediatric AA patients, corroborating the role of Th2 skewing in children with AA and associated atopy, warranting larger clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA.
- Albert Einstein College of Medicine, New York, NY, USA.
- School of Medicine, Vanderbilt University, Nashville, TN, USA.
- Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA. emma.guttman@mountsinai.org.
Zitieren
APA
David, E., Shokrian, N., Del Duca, E., Meariman, M., Glickman, J., Ghalili, S., Jung, S., Tan, K., Ungar, B., & Guttman-Yassky, E. (2024). Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Archives of Dermatological Research, 316(7). https://doi.org/10.1007/s00403-024-03225-4
Vancouver
David E, Shokrian N, Del Duca E, Meariman M, Glickman J, Ghalili S, et al. Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study. Archives of Dermatological Research. 2024;316(7). doi:10.1007/s00403-024-03225-4
BibTeX
@article{David2024,
author = {David, Eden and Shokrian, Neda and Del Duca, Ester and Meariman, Marguerite and Glickman, Jacob and Ghalili, Sabrina and Jung, Seungyeon and Tan, Kathryn and Ungar, Benjamin and Guttman-Yassky, Emma},
title = {Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study},
journal = {Archives of Dermatological Research},
year = {2024},
volume = {316},
number = {7},
doi = {10.1007/s00403-024-03225-4}
}
EUVIMED